



A New Targeted *CFTR* Mutation Panel Based on Next-Generation Sequencing Technology



Marco Lucarelli,^{*†} Luigi Porcaro,[‡] Alice Biffignandi,[‡] Lucy Costantino,[‡] Valentina Giannone,[‡] Luisella Alberti,[§] Sabina Maria Bruno,^{*} Carlo Corbetta,[§] Erminio Torresani,[¶] Carla Colombo,^{||} and Manuela Seia[‡]

From the Department of Cellular Biotechnologies and Hematology,^{*} Pasteur Institute Cenci Bolognetti Foundation,[†] Sapienza University, Rome; the Medical Genetics Laboratory,[‡] the Unit of Microbiology,[¶] Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan; the Newborn Screening Laboratory,[§] ASST Fatebenefratelli Sacco—PO Ospedale dei Bambini "V. Buzzi," Milan; and the Cystic Fibrosis Centre,^{||} Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy

Accepted for publication
June 7, 2017.

Address correspondence to
Marco Lucarelli, B.S., Dip.
Biotecnologie Cellulari ed
Ematologia, Sapienza Uni-
versità di Roma, c/o Azienda
Policlinico Umberto I, Viale
Regina Elena 324, 00161
Rome, Italy.
E-mail: marco.lucarelli@uniroma1.it

Searching for mutations in the cystic fibrosis transmembrane conductance regulator gene (*CFTR*) is a key step in the diagnosis of and neonatal and carrier screening for cystic fibrosis (CF), and it has implications for prognosis and personalized therapy. The large number of mutations and genetic and phenotypic variability make this search a complex task. Herein, we developed, validated, and tested a laboratory assay for an extended search for mutations in *CFTR* using a next-generation sequencing –based method, with a panel of 188 *CFTR* mutations customized for the Italian population. Overall, 1426 dried blood spots from neonatal screening, 402 genomic DNA samples from various origins, and 1138 genomic DNA samples from patients with CF were analyzed. The assay showed excellent analytical and diagnostic operative characteristics. We identified and experimentally validated 159 (of 188) *CFTR* mutations. The assay achieved detection rates of 95.0% and 95.6% in two large-scale case series of CF patients from central and northern Italy, respectively. These detection rates are among the highest reported so far with a genetic test for CF based on a mutation panel. This assay appears to be well suited for diagnostics, neonatal and carrier screening, and assisted reproduction, and it represents a considerable advantage in CF genetic counseling. (*J Mol Diagn* 2017, 19: 788–800; <http://dx.doi.org/10.1016/j.jmoldx.2017.06.002>)

Cystic fibrosis (CF) is a chronic, life-threatening genetic disease caused by loss-of-function mutations in the CF transmembrane conductance regulator gene (*CFTR*).^{1,2}

Notwithstanding the considerable ethnic and geographic variability in the frequency of CF, the mean incidence of 1 in 2500 live births makes CF the most frequent severe autosomal recessive disease in the white population.³ CF is characterized by wide genetic and clinical heterogeneity, which complicates diagnosis, prognosis, and therapy. From birth to adulthood, there is considerable variability in the severity and rate of disease progression in CF, with varying clinical presentations and different organs involved at different ages.⁴ Often, great phenotypic variability arises from even a single *CFTR* genotype.^{5,6}

More than 2000 different *CFTR* sequence variations, including CF-causing mutations and polymorphisms, have been reported (CFTR1 database, <http://www.genet.sickkids.on.ca>,

last accessed May 15, 2017). Also in limited geographic areas, *CFTR* shows a complete catalog of mutation types in exons, introns, the 5'-flanking region, and the 3'-untranslated region, that is, point mutations, small insertions and deletions, complex alleles, and large genomic rearrangements.^{5,7–12} This genetic heterogeneity greatly affects the allele detection rate (DR) of genetic tests, which is defined as the overall frequency of mutant alleles (of all of the mutant alleles present), as evidenced by a genetic test. For example, the DRs of the 23-mutation panel established by the American Congress of Obstetrician and Gynecologist and the

Supported by Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico Foundation and Sapienza University projects 2015.

M.L. and L.P. contributed equally to this work.

Disclosures: None declared.

American College of Medical Genetics differ substantially between various geographic regions, ranging from 49% to 94%.^{13,14} This genetic heterogeneity is further enhanced if various well-recognized clinical forms of CF, such as classic CF, CFTR-related disorders, and congenital bilateral absence of vas deferens, are taken into consideration.^{15,16} The same genetic test may have very different DRs, depending on its application in these different clinical forms.¹⁷ In this article, CF refers to the classic form of the disease and excludes CFTR-related disorders and congenital bilateral absence of vas deferens, which will be specifically mentioned when appropriate.

Limiting the scope to CF, but considering geographic areas with high genetic heterogeneity, an extended Sanger sequencing protocol of the 5'-flanking region, 27 exons and proximal intronic flanking regions, plus selected deep intronic zones for specific intron mutations in *CFTR*, have shown DRs of up to 97%.^{5,17} An additional search for large *CFTR* rearrangements showed a DR increment of approximately 2%.^{5,9,17} The high DRs of approaches with extended genetic characterization seem to be confirmed by next-generation sequencing (NGS) technology, which has been recently used for sequence and copy number variation (CNV) analyses of *CFTR*.^{18–27} NGS has been used mainly in validation studies and has been performed on a limited number of samples in comparisons of the performance of NGS to those of classic Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA). Although the NGS approach provides an obvious reduction in cost per base, and an actual possibility of multiple-gene analysis for multigenic disorders, the suitability of this approach in monogenic disorders is still debated. In particular, the classic sequencing approach and MLPA have shown excellent laboratory operative characteristics for *CFTR*.^{5,17,28,29}

Despite the excellent operative characteristics of experimental approaches based on both extended sequencing and large rearrangement search, which are welcomed for diagnostic purposes, these approaches may not be suitable for other health programs, such as neonatal and carrier screening. In fact, in addition to the obvious problems of cost and time, the functional characterization of all of the possibly identified sequence variations and the subsequent assignment of their clinical significance³⁰ may be impossible tasks. Consequently, several efforts have been made to develop experimental approaches based on selected panels of known CF-causing mutations.^{31,32} In this case, the DR of the selected panel of mutations in populations of various ethnographic origins and/or with various CF clinical forms invariably arose as a crucial variable.¹⁷ NGS platforms seem to be particularly suited to the development of mutation panels with high a mutation number and, consequently, a high DR. However, at the moment, only a small number of articles have addressed specific *CFTR* mutation panels based on NGS approaches.³³

In this work, we developed, validated, and tested a high-throughput, NGS-based approach using a customized mutation panel containing 188 CF-causing mutations in *CFTR*. We analyzed 1828 subjects referred for diagnosis and a case series of

1138 patients with CF (646 patients from northern Italy and 492 patients from central Italy). We called this assay *188-CF-NGS*. This approach revealed DRs of 95.0% and 95.6% in CF patients from central and northern Italy, respectively. Also in geographic regions with high genetic heterogeneity (such as Italy), a suitably customized and reasonably large panel of *CFTR* mutations, together with an NGS-based approach, allows the attainment of a high DR that is definitely suited for diagnostic purposes, at least in CF, and for neonatal and carrier screening.

Materials and Methods

Study Design and Case Series

We designed a specific, customized panel of 188 CF-causing mutations, described in [Supplemental Table S1](#). The mutations were included based on their high frequency in the Italian population and their documented associations with CF. Frequency information was obtained using the data on the frequency of CF mutations in Italian patients in the literature,^{5,34–39} from the 2010 Report of the Italian CF Register (<http://www.registroitalianofibrosicistica.it>, last accessed January 31, 2017), as well as from personal communication with some Italian CF centers and laboratories. The characterization of the mutations as CF causing was obtained from data on the functional effect from the North American CFTR2 (Clinical and Functional Translation of CFTR, <https://cfr2.org>, last accessed January 31, 2017) project⁴⁰ and from the literature.^{5,34,35,41} With this panel of *CFTR* mutations, we optimized an NGS-based assay we called *188-CF-NGS*.

Our assay underwent six steps of validation ([Figure 1](#)). If allowed by the overall number of mutant alleles, each mutation was validated in at least three independent samples. Also, possible differences in quality, analytical sensitivity, and analytical specificity of the 188-CF-NGS assay between analysis of dried blood spots (DBSs) and analysis of genomic DNA were evaluated.

The first validation step was the analysis of 48 selected DBSs (referred to the Newborn Screening Laboratory, ASST Fatebenefratelli Sacco—PO Ospedale dei Bambini “V. Buzzi,” Milan, Italy) that were previously investigated by mass spectrometry assay (*Mass Spectrometry Assay*). The DBSs were obtained from neonates screened as positive through the immunoreactive trypsinogen assay. The composition of this subset of DBS samples was as follows: eight homozygotes, 26 compound heterozygotes, four heterozygotes, and 10 with no *CFTR* mutation.

The second validation step was the analysis of 24 genomic DNA samples extracted from peripheral blood (referred to the Medical Genetics Laboratory, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy), which had been genotyped by confirmatory methods (*Confirmatory Methods*). The subset of 24 genomic DNA samples consisted of nine compound heterozygotes, eight heterozygotes, and seven with no *CFTR* mutation.

Study workflow




Figure 1 Study workflow of the 188-CF-NGS assay. The validation steps, specimens used, and number of mutations validated at each step, as well as overall, are reported. DBS, dried blood spots.

In the third validation step, 1378 DBSs from neonates (referred to the Newborn Screening Laboratory, Azienda Socio Sanitaria Territoriale Fatebenefratelli Sacco—PO Ospedale dei Bambini “V. Buzzi,” Milan, Italy) with elevated levels of immunoreactive trypsinogen at neonatal screening were analyzed for mutations using our 188-CF-NGS assay. All of the identified mutations were subsequently confirmed by confirmatory methods (*Confirmatory Methods*).

In the fourth validation step, 378 genomic DNA samples from subjects referred for genetic analysis (to the Medical Genetics Laboratory, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy) were analyzed using the 188-CF-NGS assay. A subset of 325 subjects underwent carrier screening

or carrier testing (211 for family history, 98 as partners of carriers, and 16 for consanguinity), and another subset (53 subjects) were analyzed for hyperechogenic bowels. All of the identified mutations were subsequently confirmed by confirmatory methods (*Confirmatory Methods*).

To complete the experimental validation of all of the mutations available in our case series, we applied a fifth validation step. We used samples from a case series comprising 1138 patients affected by CF and diagnosed according to the present guidelines⁴¹: 646 from northern Italy (referred to the Lombardia Regional Reference CF Center) and 492 from central Italy (referred to the Lazio Regional Reference CF Center). Patients with clinical manifestations associated with CFTR dysfunction but whose conditions did not fulfill the diagnostic criteria for CF (namely, CFTR-related disorders or congenital bilateral absence of vas deferens¹⁵) were not included in the case series. In the cohort from northern Italy, there were 149 patients (23%) with pancreatic sufficiency and 497 patients (77%) with pancreatic insufficiency. The age range was 2 months to 65 years. In the cohort from central Italy, there were 138 patients (28%) with pancreatic sufficiency and 354 patients (72%) with pancreatic insufficiency. The age range was 6 months to 58 years. All of the patients had undergone genetic studies, and their mutations had been identified/confirmed by confirmatory methods (*Confirmatory Methods*). This case series was also used for calculating the DRs of the 188-CF-NGS assay (in Lombardia and Lazio regions).

In the sixth validation step, all of the mutations not validated in steps 1 to 4 and not present in our case series underwent theoretical validation, also by a check of the high coverage of the corresponding targeted regions. We did not detect false-negatives related to these mutations.

All subjects provided informed consent to use the de-identified biological samples for scientific study.

DNA Extraction

Genomic DNA from peripheral blood samples, collected in EDTA tubes, was extracted from 400 μ L of blood using a QiaSymphony DSP DNA Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer’s automated protocol. For the DBS samples, DNA was extracted from three punches of 3 mm from 226 Spot Saver Cards (catalog number GR2261003; PerkinElmer, Waltham, MA) using a QIAamp DNA Investigator Kit (Qiagen), according to the manufacturer’s protocol, with 50 μ L of distilled water for the final elution step. For evaluation of the stability of the extract, all of the samples were stored at 4°C, except for four DBSs, which were extracted in duplicate and stored at –20°C; the obtained data did not reveal any differences.

Confirmatory Methods

The detection and characterization of all *CFTR* mutations in all of the subjects included in this study were also performed

with methods alternative to the 188-CF-NGS assay. These methods were applied before 188-CF-NGS in validation steps 1, 2, and 5 and after 188-CF-NGS in validation steps 3 and 4 (Figure 1). We called this group of methods *confirmatory methods*. Overall, each mutation that was identified by the 188-CF-NGS assay was always detected, in the same sample, by at least one other confirmatory method. A list of confirmatory methods and their brief descriptions are reported in the following sections.

Mass Spectrometry Assay

A mass spectrometry assay was conducted using a Myriapod Cystic Fibrosis Kit SQ080 (Sequenom, San Diego, CA), which can detect 80 mutations (including eight deletions) and the T_n tract of *CFTR*, according to the manufacturer's protocol. Briefly, DNA was amplified by multiplex PCR using eight different mixes of primers to obtain fragments corresponding to all of the regions of interest. The PCR products were treated with shrimp alkaline phosphatase (included in the SQ080 kit) to remove residual nucleotides. Then, a primer extension reaction (iPlex) with mass-modified nucleotides was performed, providing wild-type and mutant analytes of known mass. After purification and chip loading, analysis by the mass spectrometry platform resolved each analyte by its molecular weight. The obtained data were analyzed using a MassArray Analyser4 device and iGenetics Myriapod software version 4.0 (Dia- tech Pharmacogenetics, Jesi, Italy). The mass spectrometry assay was used for genetic characterization of the 48 DBS samples before the 188-CF-NGS assay preliminary validation (first validation step, *Study Design and Case Series*).⁴²

Sanger Sequencing

The regions of interest were amplified by PCR using Sensoquest Thermal Cyclers (Biomedizinische Elektronik, Hamburg, Germany). The PCR products were subsequently subjected to automated purification with a Biomek 3000 device (Beckman Coulter, Nyon, Switzerland) and Agentcourt chemistry (Beckman Coulter), followed by automated cycle sequencing with the Big Dye Terminator Cycle Sequencing Kit version 1.1 (Life Technologies, New York, NY).²⁹ Electrophoresis was performed on the ABI PRISM 3130xl platform (Life Technologies). Data analysis was performed with Sequencing Analysis software version 5.3.1 (Life Technologies) and then visualized with Seq-Scape software version 2.1.1 (Life Technologies).⁴³ In addition to the prior genetic characterization of the 24 genomic samples used for NGS preliminary validation (second validation step, *Study Design and Case Series*), and the prior genetic characterization of a subset of the case series of 1138 CF patients (fifth validation step, *Study Design and Case Series*), Sanger sequencing was also used as a confirmatory tool for the identified mutations in the 188-CF-NGS assay (those which were suitable to be characterized by sequencing) in the third and fourth validation steps.

CF-OLA Assay

The CF-OLA assay (Abbott, Wiesbaden, Germany) was used for the prior genetic characterization of a subset of the case series of 1138 CF patients (fifth validation step, *Study Design and Case Series*) according to the manufacturer's protocol. Electrophoresis was performed on the ABI PRISM 3130xl platform.

CFTR Core and CFTR Italia Assays

The CFTR Core and CFTR Italia version 2 assays (Devyser, Hagersten, Sweden) were used for the prior genetic characterization of a subset of the case series of 1138 CF patients (fifth validation step, *Study Design and Case Series*). They were also used to confirm and characterize the macrodeletions found by the 188-CF-NGS assay (those which were included in these Devyser assays) in the third and fourth validation steps. They were applied following the manufacturer's protocol. Electrophoresis was performed on the ABI PRISM 3130xl platform.

RDB-Inno LiPA CFTR17+Tn Update, CFTR19, CFTR Italian Regional and CFTR Deletions +6

RDB-Inno LiPA CFTR17+Tn Update, CFTR19, CFTR Italian Regional and CFTR Deletions +6 (Fujirebio Europe, Gent, Belgium) were used for the prior genetic characterization of a subset of the case series of 1138 CF patients (fifth validation step, *Study Design and Case Series*) according to the manufacturer's protocol.

MLPA

MLPA was performed by using the Salsa MLPA P091-D1 CFTR probe mix and reagent kit according to the manufacturer's protocol (MRC-Holland, Amsterdam, the Netherlands). Electrophoresis was performed on the ABI PRISM 3130xl platform. The data analysis was performed using the Coffalyser.net software version 140721.1958 (MRC-Holland). MLPA was used for the prior macrodeletion and macroduplication detection in samples from a subset of the case series of 1138 CF patients (fifth validation step, *Study Design and Case Series*). MLPA was also used to confirm the macrodeletions and macroduplications that were identified by the 188-CF-NGS assay (in the third and fourth validation steps) and were not included in the Devyser assays. In these cases, the breakpoints were characterized by Sanger sequencing.

NGS

The NGS experiments were performed using the commercial CFTR MASTR Dx version 2 assay (Multiplicom, Niel, Belgium). This assay enabled the targeted, multiplex PCR amplification of all coding regions, selected intronic regions, and part of the promoter region of *CFTR*, in a limited number of PCR reactions. In the first step, all targeted regions were amplified in two separate multiplex PCR amplification reactions per individual, using a hot-start

DNA polymerase. In the second step, a second round of PCR, which allowed tagging of the amplicons with molecular identifiers and MiSeq adaptors, was performed. The resulting tagged amplicons were visualized for quality control through fluorescent labeling and capillary electrophoresis on ABI PRISM 3130xl and were then pooled per individual. Each pooled amplicon library was subsequently purified from small residual DNA fragments with AMPure beads (Beckman Coulter), and the DNA concentration was determined by the Qubit dsDNA BR Assay Kit (Life Technologies). Next, purified and individually tagged amplicon libraries were pooled in equimolar samples (9 pmol/L each), along with 5% PhiX as a control (Illumina, San Diego, CA). The resulting amplicon pools were further processed on a MiSeq System with the 2 × 250 reagent kit and the MiSeq Reagent Nano kit version 2 (Illumina) according to the manufacturer's recommendations.

NGS Data Analysis

Data produced by the 188-CF-NGS assay were analyzed starting from the FastQ files generated by the MiSeq System (Illumina) using Data Driven Medicine software version 4.2.5 (Sophia Genetics, Ecublens, Switzerland).

The FastQ files were automatically uploaded and processed using patented advanced algorithms, generating a report of the entire mutation panel. For each mutation, the system specified the legacy name, its status (present/absent), the reference used for the alignment, the number of reads, and the chromosome position. When a mutation was present, the platform detailed the exon (and codon) or intron position, Human Genome Variation Society nomenclature at the DNA level and, when indicated, at the protein level, as well as the variant frequency percentage to define zygosity.

Results

Quality Metrics of the Runs

All of the runs yielded a median cluster density of 887 K/mm² (minimum 577, maximum 1080).

The mean base-call quality in each sequencing cycle was very high and typically declined slightly toward the end of the read. The distribution of mean read qualities in each data set resulted in a peak of approximately 35 to 40. The distribution of raw read lengths resulted in one or more peaks at the end of the x-scale. Regarding mapping quality, most of the mappings were of high quality, with one peak of approximately 40. If a read could not be aligned over its full length, some bases were soft-clipped at the borders of the read. However, a very small number of bases (4.50% on average) were clipped.

The mean numbers of bases and reads generated in the runs were 631.41 Mbp and 2,408,900, respectively. A read was categorized as unmapped (mean, 0.60%) if it did not align to the genome, as off target (mean, 0.31%) if it was

aligned but not within the targeted amplicons, and as on target (mean, 99.09%) if it was mapped within the amplicon regions. None of the samples in any run had <85% of reads mapping to the amplicon regions. The mean percentage of bases called incorrectly at any one cycle was 1.33% (error rate), whereas the mean percentage of bases with a quality score of 30 or higher was 95.07%. The median percentage of single clusters with a clear signal in the bases sequenced, indicated by passing filter percentage, was 95.60%.

An important prerequisite for reliable variant detection from NGS data was the coverage of targeted regions. The *base coverage* was defined as the number of reads covering a base. The *coverage of an amplicon* on a targeted region was defined as its mean base coverage. There was no region that fell within amplicons with a coverage of <50. In fact, the mean coverage achieved in the samples subjected to NGS analysis was 638 reads for each amplicon. In addition, the minimum/maximum respective values were 147/3303.

CFTR Mutations Detected by the 188-CF-NGS Assay and Validation

In [Supplemental Table S1](#), the mutations detected by the 188-CF-NGS assay are indicated according to both the old nomenclature (legacy name) and new nomenclature (Human Genome Variation Society), whereas in the text they are indicated according to legacy name only. In [Table 1](#), each mutation is assigned to the validation step in which it was first identified, although several mutations were identified several times in different validation steps. To date, we have analyzed 1828 samples and used a case series comprising 1138 CF patients ([Materials and Methods](#)) ([Figure 1](#)). For validation steps 1 and 2, 48 DBS and 24 genomic DNA samples with known mutations, respectively, were analyzed. For validation steps 3 and 4, 1378 DBSs from neonatal screening and 378 genomic DNA samples with unknown mutations, respectively, were analyzed. For validation step 5, samples from a case series of 1138 CF patients with known *CFTR* genotype were used. Step 6 was a theoretical validation of the mutations that were not found in steps 1 to 4 and were not represented in our case series.

In the 48 DBSs (validation step 1) ([Table 1](#)), we selected one small deletion (F508del), one small insertion (4016insT), four nonsense mutations (G542X, Q552X, R1162X, and W1282X), six missense mutations (T338I, D1152H, N1303K, R1066H, R117C, and R117H), and two splicing mutations (1898+1G>A and 3849+10kbC>T). In this step we validated 14 different mutations.

The analysis of the 24 genomic DNA samples (validation step 2) ([Table 1](#)) identified the following mutations: four small deletions (F508del, 1782delA, 4382delA, and 1002-1110_1113delTAAG), four nonsense mutations (E585X, G542X, Q552X, and R1162X), eight missense mutations (D1152H, G1244E, L1077P, L206W, N1303K, R1066H,

R117C, and R347P), and two splicing mutations (1717-1G>A and 3849+10kbC>T). In this step, we validated 18 different mutations, 9 of which were in addition to those from the previous step. In the first two steps, we validated a total of 23 different *CFTR* mutations.

All of the mutations found by the 188-CF-NGS assay within the first and second validation steps were correctly identified with respect to a prior genetic characterization of the same samples by a confirmatory method (*Materials and Methods*).

Among the 1378 samples selected by neonatal screening with elevated levels of immunoreactive trypsinogen (validation step 3) (Table 1), we identified 28 CF neonates (6 homozygotes and 22 compound heterozygotes) and 141 heterozygotes, with a negative sweat test. In 9 CF newborns (1 homozygote and 8 compound heterozygotes) and in 29 heterozygotes, we were able to identify 16 mutations that would not have been detected with other methods because they were not present in the mutation panels that we previously used for genetic analysis of newborns who were positive on neonatal screening. An overall number of 49 different mutations were found, 32 of which were additional to those identified using the previous two validation steps. In these three steps, we validated a total of 55 mutations.

Among the 378 genomic DNA samples (validation step 4) (Table 1), we identified 93 heterozygotes. Overall, 36 different mutations were found, 15 of which were additional to those identified using the previous three validation steps. In these four steps, we validated a total of 70 *CFTR* mutations.

In the third and fourth validation steps, all of the mutations found by the 188-CF-NGS assay were confirmed in a subsequent genetic characterization of the same samples by a confirmatory method (*Materials and Methods*).

In samples from the case series of 1138 CF patients (validation step 5) (Table 1), 84 mutations that were not validated in the previous four steps were selected, and samples from the corresponding patients were analyzed by the 188-CF-NGS assay for validation. In all of the samples analyzed in this step, all of the mutations found by the 188-CF-NGS assay were correctly identified with respect to a prior genetic characterization of the same samples by a confirmatory method (*Materials and Methods*). In all of the five validation steps, we validated a total of 154 different *CFTR* mutations of the 188 included in the 188-CF-NGS assay.

After the five validation steps, an overall number of 34 mutations were left with only theoretical validation (validation step 6) (Table 1).

Finally, the 188-CF-NGS mutation panel consisted of 188 *CFTR* mutations, 154 of which were experimentally validated and 34 were theoretically validated.

Macrodeletions, Macroduplications, and Complex Alleles in the 188-CF-NGS Assay

The 188-CF-NGS assay can detect each macrodeletion and macroduplication listed in Supplemental Table S1. If the

macrodeletion or macroduplication breakpoints are not known, a general Human Genome Variation Society notation is used. By contrast, whenever a macrodeletion or a macroduplication with characterized breakpoints exists, the specific Human Genome Variation Society name is reported. With this method, it may not be possible to directly infer the breakpoints of the identified macrodeletion or macroduplication. In these cases, further studies are needed to complete the structural characterization.

Some of the mutations included in the 188-CF-NGS assay have also been found within complex alleles. A brief description of these mutations and the corresponding complex alleles, as well as their prevalences in this case series of CF patients, are reported in Supplemental Table S2.

Operative Characteristics of the Assay

All of the 154 experimentally validated mutations, both those that were already known to be present and those that were first revealed by the 188-CF-NGS assay and then confirmed by a confirmatory method, were correctly revealed in every tested sample and replicate. Similarly, every wild-type sample and replicate was correctly characterized as negative by the 188-CF-NGS assay. Consequently, we can assign a value of 100% to the analytical sensitivity and analytical specificity of the 188-CF-NGS assay. None of the replicated samples showed discrepant results, allowing an estimation of 100% reproducibility.

The DRs (diagnostic sensitivity) of the 188-CF-NGS assay were 95.0% in the Lazio case series and 95.6% in the Lombardia case series (Table 1). As we found no false-positive results, we also report 100% overall diagnostic specificity.

The pipeline was fully automated. From an experimental point of view, the turnaround time of the platform for the complete assay in a single NGS analytical run of up to 52 samples simultaneously was 3 working days.

Discussion

This study is one of the first to apply a customized, geographically matched panel for CF disease-causing mutations using NGS technology. We validated this NGS-based assay (which we called the 188-CF-NGS assay), generating a customized panel of 188 *CFTR* mutations. This assay showed DRs of 95.0% and 95.6% in central and northern Italy, respectively, as deduced from the analysis of samples from two large-scale case series of Italian patients with CF. This assay also showed excellent values of all of the other analytical and diagnostic operative characteristics.

Due to the complex genetics and genotype–phenotype relationship of CF, an unequivocal mutation search strategy has not been delineated yet. It has been evidenced that a unique genetic test suitable for diagnostic and neonatal and carrier screening programs, as well as for all clinical forms

Table 1 Characteristics and Frequency of Mutations Included in the 188-CF-NGS Assay

Legacy name	Validation step	Type of mutation	Classification in CFTR2	Prevalence CF (PI + PS) Lazio		Prevalence CF (PI + PS) Lombardia	
				<i>n</i>	Frequency	<i>n</i>	Frequency
CFTR-dup 1–3	5	Duplication	ND	0	0.000	1	0.001
M1V	5	Missense	CF-causing	1	0.001	3	0.002
CFTRdele1	5	Deletion	CF-causing	0	0.000	1	0.001
P5L	3	Missense	ND	2	0.002	1	0.001
L15P	5	Missense	ND	0	0.000	1	0.001
175insT	4	Insertion	ND	0	0.000	0	0.000
186-13C>G	6	Splicing	ND	0	0.000	0	0.000
CFTRdele2,3	5	Deletion	CF-causing	3	0.003	3	0.002
CFTRdele2ins182	6	Deletion/Insertion	ND	0	0.000	0	0.000
CFTRdele2	5	Deletion	CF-causing	3	0.003	6	0.005
Q39X	6	Nonsense	CF-causing	0	0.000	0	0.000
296+2T>G	5	Splicing	ND	1	0.001	1	0.001
E60X	6	Nonsense	CF-causing	0	0.000	0	0.000
L61P	6	Missense	ND	0	0.000	0	0.000
R75X	5	Nonsense	CF-causing	0	0.000	1	0.001
G85E	3	Missense	CF-causing	34	0.035	13	0.010
394delTT	5	Deletion	CF-causing	0	0.000	1	0.001
406-1G>C	5	Splicing	ND	0	0.000	1	0.001
CFTRdele4	3	Deletion	ND	0	0.000	1	0.001
CFTRdele4-10	5	Deletion	ND	0	0.000	1	0.001
E92K	6	Missense	CF-causing	0	0.000	0	0.000
K95E	5	Missense	ND	0	0.000	1	0.001
457TAT>G	5	Deletion/Insertion	CF-causing	0	0.000	2	0.002
D110H	5	Missense	CF-causing	5	0.005	0	0.000
D110E	6	Missense	ND	0	0.000	0	0.000
R117C	1	Missense	CF-causing	3	0.003	5	0.004
R117H	1	Missense	Varying	0	0.000	3	0.002
R117L	5	Missense	ND	6	0.006	0	0.000
G126D	3	Missense	ND	1	0.001	0	0.000
541delC	5	Deletion	CF-causing	0	0.000	3	0.002
541del4	6	Deletion	ND	0	0.000	0	0.000
546insCTA	5	Insertion	ND	0	0.000	1	0.001
H139R	5	Missense	ND	4	0.004	0	0.000
H147P	4	Missense	ND	0	0.000	0	0.000
574delA	3	Deletion	CF-causing	3	0.003	0	0.000
621+1G>T	5	Splicing	CF-causing	8	0.008	1	0.001
663insT	5	Insertion	ND	0	0.000	1	0.001
G178R	5	Missense	CF-causing	3	0.003	3	0.002
E193K	3	Missense	ND	0	0.000	0	0.000
711+1G>T	5	Splicing	CF-causing	5	0.005	3	0.002
711+3A>G	4	Splicing	CF-causing	1	0.001	5	0.004
711+5G>A	5	Splicing	CF-causing	0	0.000	7	0.005
H199R	5	Missense	ND	1	0.001	0	0.000
P205S	6	Missense	CF-causing	0	0.000	0	0.000
L206W	2	Missense	CF-causing	0	0.000	3	0.002
G213E	5	Missense	ND	0	0.000	3	0.002
Q220X	5	Nonsense	CF-causing	1	0.001	0	0.000
852del22bp	3	Deletion	CF-causing	1	0.001	6	0.005
875+1G>A	6	Splicing	ND	0	0.000	0	0.000
C276X	5	Nonsense	CF-causing	2	0.002	0	0.000
991del5	5	Nonsense	CF-causing	1	0.001	0	0.000
1002-1110_1113delTAAG	2	Deletion	ND	0	0.000	3	0.002
1002-1111A>C	4	Splicing	ND	0	0.000	0	0.000
A309D	5	Missense	ND	0	0.000	1	0.001
1078delT	5	Deletion	CF-causing	0	0.000	1	0.001

(table continues)

Table 1 (continued)

Legacy name	Validation step	Type of mutation	Classification in CFTR2	Prevalence CF (PI + PS) Lazio		Prevalence CF (PI + PS) Lombardia	
				<i>n</i>	Frequency	<i>n</i>	Frequency
R334W	3	Missense	CF-causing	8	0.008	8	0.006
R334L	5	Missense	ND	5	0.005	0	0.000
T338I	1	Missense	CF-causing	5	0.005	7	0.005
R347H	5	Missense	CF-causing	3	0.003	2	0.002
R347P	2	Missense	CF-causing	7	0.007	7	0.005
R352W	3	Missense	ND	0	0.000	0	0.000
R352Q	3	Missense	CF-causing	0	0.000	14	0.011
Q353X	6	Nonsense	ND	0	0.000	0	0.000
1248+1G>A	5	Splicing	CF-causing	0	0.000	2	0.002
1249-1G>A	5	Splicing	CF-causing	0	0.000	1	0.001
1259InsA	3	Insertion	CF-causing	1	0.001	1	0.001
1497delGG	6	Deletion	CF-causing	0	0.000	0	0.000
V456A	6	Missense	ND	0	0.000	0	0.000
G463D	4	Missense	ND	0	0.000	0	0.000
K464N	5	Missense	ND	0	0.000	2	0.002
S466X(TAA)	3	Nonsense	CF-causing	0	0.000	0	0.000
S466X(TGA)	5	Nonsense	CF-causing	3	0.003	0	0.000
1565delCA	6	Deletion	ND	0	0.000	0	0.000
Q493X	6	Nonsense	ND	0	0.000	0	0.000
E504X	5	Nonsense	ND	0	0.000	1	0.001
[delta]I507	5	Deletion	CF-causing	0	0.000	1	0.001
[delta]F508	1	Deletion	CF-causing	440	0.447	608	0.471
1677delTA	3	Deletion	CF-causing	0	0.000	3	0.002
Q525X	6	Nonsense	CF-causing	0	0.000	0	0.000
1706del17	6	Deletion	ND	0	0.000	0	0.000
CFTRdele11	4	Deletion	CF-causing	0	0.000	0	0.000
1716+18672A>G	5	Splicing	ND	0	0.000	4	0.003
1717-8G>A	5	Splicing	CF-causing	2	0.002	1	0.001
1717-1G>A	2	Splicing	CF-causing	15	0.015	41	0.032
G542X	1	Nonsense	CF-causing	43	0.044	64	0.050
S549R(A>C)	5	Missense	CF-causing	12	0.012	0	0.000
S549N	5	Missense	CF-causing	2	0.002	1	0.001
S549R(T>G)	4	Missense	CF-causing	7	0.007	0	0.000
1782delA	2	Deletion	CF-causing	0	0.000	4	0.003
1784delG	5	Deletion	ND	0	0.000	1	0.001
G551D	5	Missense	CF-causing	1	0.001	0	0.000
Q552X	1	Nonsense	CF-causing	1	0.001	1	0.001
R553X	5	Nonsense	CF-causing	13	0.013	12	0.009
V562I	3	Missense	ND	0	0.000	1	0.001
Y563X	5	Nonsense	ND	0	0.000	2	0.002
L571S	5	Missense	ND	1	0.001	1	0.001
1845delAG/1846delGA	5	Deletion	ND	0	0.000	1	0.001
D579G	3	Missense	Varying	1	0.001	5	0.004
1874insT	6	Insertion	ND	0	0.000	0	0.000
E585X	2	Nonsense	CF-causing	3	0.003	11	0.009
S589I	4	Missense	ND	0	0.000	0	0.000
1898+1G>A	1	Splicing	CF-causing	0	0.000	5	0.004
1898+3A>G	6	Splicing	CF-causing	0	0.000	0	0.000
1898+5G>T	5	Splicing	ND	0	0.000	1	0.001
S589R	4	Missense	ND	0	0.000	0	0.000
K598X	5	Nonsense	ND	0	0.000	1	0.001
1949del84	4	Deletion	ND	0	0.000	0	0.000
H609R	5	Missense	ND	0	0.000	2	0.002
A613T	5	Missense	ND	1	0.001	1	0.001
D614G	4	Missense	Varying	6	0.006	0	0.000

(table continues)

Table 1 (continued)

Legacy name	Validation step	Type of mutation	Classification in CFTR2	Prevalence CF (PI + PS) Lazio		Prevalence CF (PI + PS) Lombardia	
				<i>n</i>	Frequency	<i>n</i>	Frequency
H620P	5	Missense	ND	0	0.000	1	0.001
2118del4	3	Deletion	CF-causing	0	0.000	1	0.001
2143delT	5	Deletion	CF-causing	1	0.001	0	0.000
G673X	6	Nonsense	CF-causing	0	0.000	0	0.000
2183AA>G	3	Deletion/Insertion	CF-causing	12	0.012	20	0.015
2184delA	6	Deletion	CF-causing	0	0.000	0	0.000
2184insA	5	Insertion	CF-causing	6	0.006	2	0.002
2185insC	6	Insertion	CF-causing	0	0.000	0	0.000
R709X	5	Nonsense	CF-causing	3	0.003	0	0.000
Q720X	5	Nonsense	ND	0	0.000	1	0.001
2307insA	6	Insertion	CF-causing	0	0.000	0	0.000
L732X	5	Nonsense	CF-causing	2	0.002	1	0.001
R764X	5	Nonsense	CF-causing	1	0.001	0	0.000
R785X	3	Nonsense	CF-causing	0	0.000	1	0.001
2585delT	6	Deletion	CF-causing	0	0.000	0	0.000
E822X	4	Nonsense	CF-causing	0	0.000	0	0.000
E831X	5	Nonsense	CF-causing	1	0.001	2	0.002
Y849X	5	Nonsense	CF-causing	1	0.001	0	0.000
R851X	5	Nonsense	CF-causing	0	0.000	1	0.001
2711delT	5	Deletion	CF-causing	0	0.000	1	0.001
CFTRdele14b-17b	5	Deletion	CF-causing	1	0.001	5	0.004
W882X	5	Nonsense	ND	0	0.000	1	0.001
2789+5G>A	3	Splicing	CF-causing	40	0.041	39	0.030
2790-2A>G	5	Splicing	ND	1	0.001	0	0.000
2811G>T	6	Splicing	ND	0	0.000	0	0.000
S912X	3	Nonsense	CF-causing	1	0.001	0	0.000
2909delT	6	Deletion	ND	0	0.000	0	0.000
S945L	5	Missense	CF-causing	2	0.002	1	0.001
G970R	6	Missense	CF-causing	0	0.000	0	0.000
CFTRdele17a-18	3	Deletion	CF-causing	4	0.004	2	0.002
3121-2A>T	6	Splicing	CF-causing	0	0.000	0	0.000
3121-1G>A	6	Splicing	CF-causing	0	0.000	0	0.000
3132delTG	6	Deletion	CF-causing	0	0.000	0	0.000
A1006E	5	Missense	ND	0	0.000	1	0.001
[V562I;A1006E]	5	Complex Allele	ND	9	0.009	1	0.001
Q1012X	4	Nonsense	ND	0	0.000	0	0.000
3199del6	6	Deletion	ND	0	0.000	0	0.000
Y1032C	3	Missense	ND	0	0.000	0	0.000
CFTRdele17b	5	Deletion	ND	0	0.000	1	0.001
3272-26A>G	3	Splicing	CF-causing	1	0.001	2	0.002
H1054D	5	Missense	CF-causing	0	0.000	1	0.001
L1065P	5	Missense	CF-causing	6	0.006	0	0.000
R1066C	3	Missense	CF-causing	5	0.005	9	0.007
R1066H	1	Missense	CF-causing	1	0.001	23	0.018
F1074L	3	Missense	Varying	0	0.000	1	0.001
L1077P	2	Missense	CF-causing	12	0.012	15	0.012
M1101K	5	Missense	CF-causing	0	0.000	2	0.002
E1104X	3	Nonsense	CF-causing	0	0.000	1	0.001
W1145X	5	Nonsense	ND	0	0.000	1	0.001
D1152H	1	Missense	Varying	7	0.007	23	0.018
R1158X	3	Nonsense	CF-causing	0	0.000	10	0.008
[R334W;R1158X]	3	Complex Allele	ND	0	0.000	0	0.000
R1162X	1	Nonsense	CF-causing	3	0.003	4	0.003
3659delC	4	Deletion	CF-causing	0	0.000	2	0.002
S1206X	5	Nonsense	ND	1	0.001	1	0.001

(table continues)

Table 1 (continued)

Legacy name	Validation step	Type of mutation	Classification in CFTR2	Prevalence CF (PI + PS) Lazio		Prevalence CF (PI + PS) Lombardia	
				<i>n</i>	Frequency	<i>n</i>	Frequency
M1210K	5	Missense	ND	0	0.000	2	0.002
I1234V	5	Missense	CF-causing	3	0.003	0	0.000
3849+10kbC>T	1	Splicing	CF-causing	9	0.009	21	0.016
G1244E	2	Missense	CF-causing	4	0.004	8	0.006
3876delA	6	Deletion	CF-causing	0	0.000	0	0.000
3878delG	5	Deletion	CF-causing	0	0.000	1	0.001
S1251N	5	Missense	CF-causing	0	0.000	1	0.001
3905insT	3	Insertion	CF-causing	0	0.000	0	0.000
D1270N	3	Missense	Varying	1	0.001	0	0.000
W1282X	1	Nonsense	CF-causing	47	0.048	19	0.015
Q1291R	3	Missense	ND	3	0.003	0	0.000
CFTRdele21	5	Deletion	ND	0	0.000	1	0.001
4015delA	5	Deletion	CF-causing	0	0.000	3	0.002
4016insT	1	Insertion	CF-causing	1	0.001	15	0.012
4040delA	5	Deletion	CF-causing	2	0.002	0	0.000
N1303K	1	Missense	CF-causing	61	0.062	64	0.050
Q1313X	6	Nonsense	CF-causing	0	0.000	0	0.000
CFTRdele22-24	5	Deletion/Insertion	CF-causing	7	0.007	3	0.002
CFTRdele22-23	4	Deletion	CF-causing	1	0.001	4	0.003
G1349D	3	Missense	CF-causing	2	0.002	1	0.001
4209TGTT>AA	6	Deletion/Insertion	CF-causing	0	0.000	0	0.000
H1375P	5	Missense	ND	3	0.003	2	0.002
4382delA	2	Deletion	CF-causing	0	0.000	6	0.005
S1455X	3	Nonsense	ND	1	0.001	1	0.001
E1473X	5	Nonsense	ND	0	0.000	2	0.002
Detected alleles				935		1235	
Unknown alleles				49		57	
Overall alleles				984		1292	
Detection rate					0.950 (95.0%)		0.956 (95.6%)

The mutations are listed only in old nomenclature (legacy name; refer to [Supplemental Table S1](#) for Human Genome Variation Society nomenclature). The Validation step column refers to the following validation procedures ([Materials and Methods](#)): 1 = validated in the first step by the selected 48 dried blood spots (DBSs); 2 = validated in the second step by the selected 24 genomic DNA; 3 = validated in the third step by the subsequent 1378 DBSs; 4 = validated in the fourth step by the subsequent 378 genomic DNA; 5 = validated in the fifth step by the 1138 cystic fibrosis (CF) patient case series; 6 = validated only at theoretic level. The type of mutations and the functional classification according to CFTR2 database is reported. The prevalence of each mutation in both the Lazio and Lombardia case series is reported as number (*n*) and frequency of alleles; the corresponding DRs are also shown.

CF-causing, mutation that causes classic form of CF; ND, mutation not reported in the CFTR2 database; PI, pancreatic insufficiency; PS, pancreatic sufficiency; Varying, mutation with variable clinical effect.

of CF, does not exist.¹⁷ A multistep genetic approach is usually applied for diagnostic purposes.^{5,17} The first step is to search for a panel of frequent *CFTR* mutations. The DRs of CF mutation panels are different in diverse populations³³ and depend on the clinical form.¹⁷ Consequently, this step leaves a variable proportion of alleles with no mutation detected. To characterize these unknown alleles, a second step of sequencing (usually sequencing of all of the exons, adjacent intronic zones, and proximal 5'-flanking region of *CFTR*) is applied. Sequencing of *CFTR*, when applied for diagnostic purposes based on either classic Sanger sequencing or NGS, is reported to detect approximately 97% of disease-causing mutations, at least in CF.^{5,17,44} In *CFTR*-related disorders and congenital bilateral absence of vas deferens, even sequencing may have a low DR.^{5,17,44} Those mutations possibly not recognized, for example

macrodeletions and macroduplications, are usually investigated in a third step of mutation search to reveal CNVs. It is expected that this step will add up to 2% to the DR. Although a sequencing protocol, possibly followed by a CNV search, may be suitable for diagnostic purposes, it does not appear to be recommendable for carrier or neonatal screening. This is especially true if a powerful approach, such as NGS, is used.⁴⁵ The DR of an extended mutation panel by NGS, including frequent and characterized CNVs, usually is sufficiently high for carrier and neonatal screening purposes. On the other hand, sequencing (and in some cases also CNV analysis) may identify not only disease-causing mutations possibly undetected by commonly used panels, but also novel or rare *CFTR* variants the clinical significance of which has not been assessed, or variants associated with a broad phenotypic spectrum. In addition, novel CNVs

usually need further structural characterization. When mutation-identification assays, such as sequencing, are used, novel variants are identified in an estimated ~ 1 in 500 samples that are tested for carrier status.⁴⁶ In addition, to limit costs and time, even for diagnostic purposes in CF, it may be suitable to start the mutation search with a mutation panel. For these reasons, protocols based on mutation panels still have a role in mutational searches performed for both CF diagnostics and screening purposes, even in the NGS era.

The DR reached by our 188-CF-NGS assay is among the highest achieved by a genetic test for CF based on a mutation panel (level I assay) in a population with high genetic heterogeneity of *CFTR*. For example, the Food and Drug Administration–approved MiSeqDX Cystic Fibrosis 139-variant assay (Illumina), an NGS mutation panel that was not specifically optimized for central or northern Italy, shows DRs considerably lower than that of our assay in both regions of Italy (central, 86.8%; northern, 86.9%), as deduced from the analysis of data from our case series. This result highlights that, despite the power of extended mutation panels based on NGS technology, customization is still required to achieve maximal DRs in specific geographic areas and, conceivably, in ethnicities and clinical forms. Moreover, there may be geographic areas with even higher genetic heterogeneity than that of Italy where a similarly high DR may not be reached, even with a widely targeted NGS mutation panel. Although the definition of a mutation search as a first-level test is irrespective of the number of mutations included in the panel, it is evident that NGS greatly enhances this approach by using wider mutation panels. Owing to this enhancement, the gap between the DRs shown by the same mutation panel in different geographic areas, ethnicities, and CF clinical forms will decrease. However, due to rare and often individual mutations¹⁷ and high geographic heterogeneity, the use of only one large mutation panel that is suitable for all purposes remains unlikely.

A common problem of mutation panels is that of complex alleles, which contain more than one mutation in *cis*. It is becoming clear that complex alleles occur more frequently than is usually recognized. We chose to include at least one mutation of the most frequent complex alleles in the 188-CF-NGS assay and to supply a list of mutations that would have been searched for in cases in which a potentially associated mutation was found. It is obvious that the complete panel of mutations within complex alleles can be easily added to the Data Driven Medicine platform (Sophia Genetics). Presently, the Data Driven Medicine platform lets users unmask the analysis of the (TG)_mT_n variant tract when one of the following mutations is detected: R117C, R117H, K464N, V562I, A1006E, or 2184insA (Supplemental Table S2).

The validation of the 188-CF-NGS assay on DBSs showed excellent operative characteristics that are fully comparable to those of genomic DNA samples. This result makes the assay also suitable for the genetic step of neonatal

screening programs, such as the immunoreactive trypsinogen/DNA/immunoreactive trypsinogen protocol.^{47,48}

Another characteristic that makes the 188-CF-NGS assay attractive is the possibility that when no mutations or only one mutation is identified in individuals potentially affected by CF, a different profiling analysis can be applied with the Data Driven Medicine platform, unmasking the complete sequence of *CFTR*. Furthermore, the *CFTR* sequence acquired by this NGS approach can reveal CNVs by analyzing the number of reads, including the identification of *CFTR* macrodeletions and macroduplications. The possibility of applying all three steps of the mutation search (also combining the second and third steps) according to the requirements of the applied protocol and by only switching software settings represent considerable enhancements with respect to previous multi-step approaches. Improved *CFTR* genotyping is expected from the 188-CF-NGS assay due to the speediness, simplicity, and high-throughput nature of the assay, as well as its predictable, enhanced identification of complex alleles.

As NGS methods are still in the experimental phase, confirmation by an independent method seems to be appropriate. Depending on the type of mutation evidenced, an appropriate confirmatory method (*Materials and Methods*) was applied. There was perfect concordance between the data obtained with the 188-CF-NGS assay and the confirmatory methods. Although it may still be untimely to abandon the confirmatory procedure, these results further highlight the reliability of NGS-based approaches as stand-alone methods.

A turnaround time of 3 working days for up to 52 samples seems suitable for overcoming the wait-time issues related to the collection of an appropriate number of samples. From a data analysis point of view, the type of analysis can be selected according to clinical indications. The algorithm of the Data Driven Medicine platform was specifically adapted to our needs to accurately perform DNA sequence assembly, alignment to the reference genome, variant calling, and variant annotation in a short time for level I analysis (panel), and one can easily proceed, if indicated, to analysis levels II (sequence) and III (macrodeletions/microduplications). Also, the (TG)_mT_n tracts can be easily analyzed if needed.

In conclusion, the 188-CF-NGS assay is a robust method that is easy to handle and that allows the detection of approximately 95% of the mutations in the Italian population, thus achieving a marked increase in DR compared with those of other NGS-based mutation panel methods. This result highlights the concept that despite the high number of *CFTR* mutations that can be searched by NGS methods, the customization of mutation panels for a geographic area and, conceivably, for ethnicities and clinical forms, is still advisable. The availability of an extended mutation panel with a high DR is useful for limiting the use of sequencing and for avoiding the detection of DNA variants with unclear functional meaning. It enhances the ability to obtain an early, complete definition of mutated genotypes in CF patients, providing a meaningful genotypic-oriented view of *CFTR* genetics.⁵ Our assay is well suited for CF diagnostic

purposes, neonatal screening, and carrier screening, and has also been finalized for assisted reproductive technology. It might also show good performance for CFTR-related disorders and congenital bilateral absence of vas deferens; however, experimental verification seems appropriate. Experimental approaches based on extended panels of mutations for NGS, such as the one described here, greatly facilitate the task of finding mutations, providing a better definition of the genotype–phenotype relationship. Overall, these findings clearly have positive implications for the genetic counseling of CF. Finally, the synergy between NGS approaches and the actual possibility of personalized CF therapy is anticipated to produce unparalleled advantages for CF patients. NGS approaches help to reduce possibly incomplete genotyping, which may hamper the therapeutic response to a mutation-specific therapy. This enhanced knowledge of *CFTR* genetics may finally allow the physician to apply both predictive and preventive medicine in CF.⁴⁹

Acknowledgments

We thank the Veneto Regional CF Center, Hospital of Verona (Verona, Italy; Alberto Bonizzato), the Molecular Genetics Laboratory, Unit of Medical Genetics, University of Ferrara (Ferrara, Italy; Anna Ravani), the Tor Vergata Policlinico Foundation, (Rome, Italy; Maria Rosaria D'Apice); and the Human Genetics Laboratory, Galliera Hospital, (Genova, Italy; Ave Maria Baffico) for helpful discussions about the *CFTR* mutations suitable for inclusion in a customized panel for Italy. We thank the Lazio Regional Reference CF Center (Rome, Italy) for the availability and clinical characterization of the case series from central Italy.

Supplemental Data

Supplemental material for this article can be found at <http://dx.doi.org/10.1016/j.jmoldx.2017.06.002>.

References

- Lucarelli M, Pierandrei S, Bruno SM, Strom R: The genetics of CFTR: genotype – phenotype relationship, diagnostic challenge and therapeutic implications. *Cystic Fibrosis - Renewed Hopes Through Research*. Edited by Sriramulu D. Rijeka, Croatia: Intech, 2012. pp. 91–122
- Bombieri C, Seia M, Castellani C: Genotypes and phenotypes in cystic fibrosis and cystic fibrosis transmembrane regulator-related disorders. *Semin Respir Crit Care Med* 2015, 36:180–193
- Rowntree RK, Harris A: The phenotypic consequences of CFTR mutations. *Ann Hum Genet* 2003, 67:471–485
- Castellani C, Cuppens H, Macek M Jr, Cassiman JJ, Kerem E, Durie P, Tullis E, Assael BM, Bombieri C, Brown A, Casals T, Claustres M, Cutting GR, Dequeker E, Dodge J, Doull I, Farrell P, Ferec C, Girodon E, Johannesson M, Kerem B, Knowles M, Munck A, Pignatti PF, Radojkovic D, Rizzotti P, Schwarz M, Stuhmann M,

- Tzetis M, Zielenski J, Elborn JS: Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. *J Cyst Fibros* 2008, 7:179–196
- Lucarelli M, Bruno SM, Pierandrei S, Ferraguti G, Stamato A, Narzi F, Amato A, Cimino G, Bertasi S, Quattrucci S, Strom R: A genotypic-oriented view of CFTR genetics highlights specific mutational patterns underlying clinical macrocategories of cystic fibrosis. *Mol Med* 2015, 21:257–275
- Terlizzi V, Carnovale V, Castaldo G, Castellani C, Cirilli N, Colombo C, Corti F, Cresta F, D'Adda A, Lucarelli M, Lucidi V, Macchiaroli A, Madarena E, Padoan R, Quattrucci S, Salvatore D, Zarrilli F, Raia V: Clinical expression of patients with the D1152H CFTR mutation. *J Cyst Fibros* 2015, 14:447–452
- Costantino L, Claut L, Paracchini V, Coviello DA, Colombo C, Porcaro L, Capasso P, Zanardelli M, Pizzamiglio G, Degiorgio D, Seia M: A novel donor splice site characterized by CFTR mRNA analysis induces a new pseudo-exon in CF patients. *J Cyst Fibros* 2010, 9:411–418
- Lucarelli M, Narzi L, Pierandrei S, Bruno SM, Stamato A, d'Avanzo M, Strom R, Quattrucci S: A new complex allele of the CFTR gene partially explains the variable phenotype of the L997F mutation. *Genet Med* 2010, 12:548–555
- Paracchini V, Seia M, Coviello D, Porcaro L, Costantino L, Capasso P, Degiorgio D, Padoan R, Corbetta C, Claut L, Costantini D, Colombo C: Molecular and clinical features associated with CFTR gene rearrangements in Italian population: identification of a new duplication and recurrent deletions. *Clin Genet* 2008, 73: 346–352
- Amato F, Seia M, Giordano S, Elce A, Zarrilli F, Castaldo G, Tomaiuolo R: Gene mutation in microRNA target sites of CFTR gene: a novel pathogenetic mechanism in cystic fibrosis? *PLoS One* 2013, 8:e60448
- Castaldo G, Tomaiuolo R: What is the role of the non-coding regions of the CFTR gene in cystic fibrosis? *Expert Rev Respir Med* 2013, 7: 327–329
- Lucarelli M: A commentary on the novel complex allele [A238V; F508del] of the CFTR gene: clinical phenotype and possible implications for cystic fibrosis etiological therapies. *J Hum Genet* 2016, 61: 471–472
- American College of Obstetricians and Gynecologists Committee on Genetics: ACOG Committee Opinion No. 486: update on carrier screening for cystic fibrosis. *Obstet Gynecol* 2011, 117:1028–1031
- Lao O, Andres AM, Mateu E, Bertranpetit J, Calafell F: Spatial patterns of cystic fibrosis mutation spectra in European populations. *Eur J Hum Genet* 2003, 11:385–394
- Bombieri C, Claustres M, De BK, Derichs N, Dodge J, Girodon E, Sermet I, Schwarz M, Tzetis M, Wilschanski M, Bareil C, Bilton D, Castellani C, Cuppens H, Cutting GR, Drevinek P, Farrell P, Elborn JS, Jarvi K, Kerem B, Kerem E, Knowles M, Macek M Jr, Munck A, Radojkovic D, Seia M, Sheppard DN, Southern KW, Stuhmann M, Tullis E, Zielenski J, Pignatti PF, Ferec C: Recommendations for the classification of diseases as CFTR-related disorders. *J Cyst Fibros* 2011, 10 Suppl 2:S86–S102
- Rossi T, Grandoni F, Mazzilli F, Quattrucci S, Antonelli M, Strom R, Lucarelli M: High frequency of (TG)_mTn variant tracts in the cystic fibrosis transmembrane conductance regulator gene in men with high semen viscosity. *Fertil Steril* 2004, 82:1316–1322
- Lucarelli M, Bruno SM, Pierandrei S, Ferraguti G, Testino G, Truglio G, Strom R, Quattrucci S: The impact on genetic testing of mutational patterns of CFTR gene in different clinical macrocategories of cystic fibrosis. *J Mol Diagn* 2016, 18:554–565
- Pagin A, Devos A, Figeac M, Truant M, Willouquaux C, Broly F, Lalau G: Applicability and efficiency of NGS in routine diagnosis: in-depth performance analysis of a complete workflow for CFTR mutation analysis. *PLoS One* 2016, 11:e0149426
- Lefterova MI, Shen P, Odegaard JJ, Fung E, Chiang T, Peng G, Davis RW, Wang W, Kharrazi M, Schrijver I, Scharfe C: Next-generation molecular testing of newborn dried blood spots for cystic fibrosis. *J Mol Diagn* 2016, 18:267–282

20. Grosu DS, Hague L, Chelliserry M, Kruglyak KM, Lenta R, Klotzle B, San J, Goldstein WM, Moturi S, Devers P, Woolworth J, Peters E, Elashoff B, Stoerker J, Wolff DJ, Friedman KJ, Highsmith WE, Lin E, Ong FS: Clinical investigation studies for validation of a next-generation sequencing in vitro diagnostic device for cystic fibrosis testing. *Expert Rev Mol Diagn* 2014, 14:605–622
21. Baker MW, Atkins AE, Cordovado SK, Hendrix M, Earley MC, Farrell PM: Improving newborn screening for cystic fibrosis using next-generation sequencing technology: a technical feasibility study. *Genet Med* 2016, 18:231–238
22. Trujillano D, Ramos MD, Gonzalez J, Tornador C, Sotillo F, Escaramis G, Ossowski S, Armengol L, Casals T, Estivill X: Next generation diagnostics of cystic fibrosis and CFTR-related disorders by targeted multiplex high-coverage resequencing of CFTR. *J Med Genet* 2013, 50:455–462
23. Trujillano D, Weiss ME, Koster J, Papachristos EB, Werber M, Kandaswamy KK, Marais A, Eichler S, Creed J, Baysal E, Jaber IY, Mehane DA, Farra C, Rolfs A: Validation of a semiconductor next-generation sequencing assay for the clinical genetic screening of CFTR. *Mol Genet Genomic Med* 2015, 3:396–403
24. Loukas YL, Thodi G, Molou E, Georgiou V, Dotsikas Y, Schulpis KH: Clinical diagnostic next-generation sequencing: the case of CFTR carrier screening. *Scand J Clin Lab Invest* 2015, 75:374–381
25. Essawi O, Farraj M, De LK, Steyaert W, De PK, De PA, Claes K, Essawi T, Coucke PJ: Next generation sequencing to determine the cystic fibrosis mutation spectrum in Palestinian population. *Dis Markers* 2015, 2015:458653
26. Nakano E, Masamune A, Niihori T, Kume K, Hamada S, Aoki Y, Matsubara Y, Shimosegawa T: Targeted next-generation sequencing effectively analyzed the cystic fibrosis transmembrane conductance regulator gene in pancreatitis. *Dig Dis Sci* 2015, 60:1297–1307
27. Abou Tayoun AN, Tunkey CD, Pugh TJ, Ross T, Shah M, Lee CC, Harkins TT, Wells WA, Tafe LJ, Amos CI, Tsongalis GJ: A comprehensive assay for CFTR mutational analysis using next-generation sequencing. *Clin Chem* 2013, 59:1481–1488
28. Lucarelli M, Grandoni F, Rossi T, Mazzilli F, Antonelli M, Strom R: Simultaneous cycle sequencing assessment of (TG)_m and Tn tract length in CFTR gene. *Biotechniques* 2002, 32:540–547
29. Lucarelli M, Narzi L, Piergentili R, Ferraguti G, Grandoni F, Quattrucci S, Strom R: A 96-well formatted method for exon and exon/intron boundary full sequencing of the CFTR gene. *Anal Biochem* 2006, 353:226–235
30. Terlizzi V, Castaldo G, Salvatore D, Lucarelli M, Raia V, Angioni A, Carnovale V, Cirilli N, Casciaro R, Colombo C, Di Lullo AM, Elce A, Iacotucci P, Comegna M, Scorza M, Lucidi V, Perfetti A, Cimino R, Quattrucci S, Seia M, Sofia VM, Zarrilli F, Amato F: Genotype-phenotype correlation and functional studies in patients with cystic fibrosis bearing CFTR complex alleles. *J Med Genet* 2017, 54:224–235
31. Bickmann JK, Kamin W, Wiebel M, Hauser F, Wenzel JJ, Neukirch C, Stuhmann M, Lackner KJ, Rossmann H: A novel approach to CFTR mutation testing by pyrosequencing-based assay panels adapted to ethnicities. *Clin Chem* 2009, 55:1083–1091
32. Stoerker J, Goodman TG, Walline HM, Sugalski J, Holland CA: Evaluation of a BeadXpress assay for a 151-mutation and variant CFTR screening panel after 11,000 samples: implications for practice. *Diagn Mol Pathol* 2013, 22:144–148
33. Hughes EE, Stevens CF, Saavedra-Matiz CA, Tavakoli NP, Krein LM, Parker A, Zhang Z, Maloney B, Vogel B, DeCelie-Germana J, Kier C, Anbar RD, Berdella MN, Comber PG, Dozor AJ, Goetz DM, Guida L Jr, Kattan M, Ting A, Voter KZ, van Roey P, Caggana M, Kay DM: Clinical sensitivity of cystic fibrosis mutation panels in a diverse population. *Hum Mutat* 2016, 37:201–208
34. Castaldo G, Polizzi A, Tomaiuolo R, Cazeneuve C, Girodon E, Santostasi T, Salvatore D, Raia V, Rigillo N, Goossens M, Salvatore F: Comprehensive cystic fibrosis mutation epidemiology and haplotype characterization in a southern Italian population. *Ann Hum Genet* 2005, 69:15–24
35. Bombieri C, Bonizzato A, Castellani C, Assael BM, Pignatti PF: Frequency of large CFTR gene rearrangements in Italian CF patients. *Eur J Hum Genet* 2005, 13:687–689
36. Coiana A, Faa' V, Carta D, Puddu R, Cao A, Rosatelli MC: Pre-conceptional identification of cystic fibrosis carriers in the Sardinian population: a pilot screening program. *J Cyst Fibros* 2011, 10:207–211
37. Rendine S, Calafell F, Cappello N, Gagliardini R, Caramia G, Rigillo N, Silveti M, Zanda M, Miano A, Battistini F, Marianelli L, Taccetti G, Diana MC, Romano L, Romano C, Giunta A, Padoan R, Pianaroli A, Raia V, De RG, Battistini A, Grzincich G, Japichino L, Pardo F, Piazza A: Genetic history of cystic fibrosis mutations in Italy. I. Regional distribution. *Ann Hum Genet* 1997, 61(Pt 5):411–424
38. Tomaiuolo R, Sanguolo F, Bombieri C, Bonizzato A, Cardillo G, Raia V, D'Apice MR, Bettin MD, Pignatti PF, Castaldo G, Novelli G: Epidemiology and a novel procedure for large scale analysis of CFTR rearrangements in classic and atypical CF patients: a multicentric Italian study. *J Cyst Fibros* 2008, 7:347–351
39. Picci L, Cameran M, Marangon O, Marzenta D, Ferrari S, Frigo AC, Scarpa M: A 10-year large-scale cystic fibrosis carrier screening in the Italian population. *J Cyst Fibros* 2010, 9:29–35
40. Sosnay PR, Siklosi KR, Van GF, Kaniecki K, Yu H, Sharma N, Ramalho AS, Amaral MD, Dorfman R, Zielenski J, Masica DL, Karchin R, Millen L, Thomas PJ, Patrinos GP, Corey M, Lewis MH, Rommens JM, Castellani C, Penland CM, Cutting GR: Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. *Nat Genet* 2013, 45:1160–1167
41. Dequeker E, Stuhmann M, Morris MA, Casals T, Castellani C, Claustres M, Cuppens H, Des GM, Ferec C, Macek M, Pignatti PF, Scheffer H, Schwartz M, Witt M, Schwarz M, Girodon E: Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders—updated European recommendations. *Eur J Hum Genet* 2009, 17:51–65
42. Buyse IM, McCarthy SE, Lurix P, Pace RP, Vo D, Bartlett GA, Schmitt ES, Ward PA, Oermann C, Eng CM, Roa BB: Use of MALDI-TOF mass spectrometry in a 51-mutation test for cystic fibrosis: evidence that 3199del6 is a disease-causing mutation. *Genet Med* 2004, 6:426–430
43. Ferraguti G, Pierandrei S, Bruno SM, Ceci F, Strom R, Lucarelli M: A template for mutational data analysis of the CFTR gene. *Clin Chem Lab Med* 2011, 49:1447–1451
44. Strom CM, Huang D, Chen C, Buller A, Peng M, Quan F, Redman J, Sun W: Extensive sequencing of the cystic fibrosis transmembrane regulator gene: assay validation and unexpected benefits of developing a comprehensive test. *Genet Med* 2003, 5:9–14
45. Almannai M, Marom R, Sutton VR: Newborn screening: a review of history, recent advancements, and future perspectives in the era of next generation sequencing. *Curr Opin Pediatr* 2016, 28:694–699
46. Merelle ME, Scheffer H, De JD, Dankert-Roelse JE: Extended gene analysis can increase specificity of neonatal screening for cystic fibrosis. *Acta Paediatr* 2006, 95:1424–1428
47. Narzi L, Lucarelli M, Lelli A, Grandoni F, Lo CS, Ferraro A, Matarazzo P, Delaroché I, Quattrucci S, Strom R, Antonelli M: Comparison of two different protocols of neonatal screening for cystic fibrosis. *Clin Genet* 2002, 62:245–249
48. Narzi L, Ferraguti G, Stamato A, Narzi F, Valentini SB, Lelli A, Delaroché I, Lucarelli M, Strom R, Quattrucci S: Does cystic fibrosis neonatal screening detect atypical CF forms? Extended genetic characterization and 4-year clinical follow-up. *Clin Genet* 2007, 72:39–46
49. Corvol H, Thompson KE, Tabary O, le Rouzic P, Guillot L: Translating the genetics of cystic fibrosis to personalized medicine. *Transl Res* 2016, 168:40–49